Global Orally Inhaled Bronchodilators Market to 2022

DUBLIN, Apr. 09, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/v3tw68/orally_inhaled) has announced the addition of the "Orally Inhaled Bronchodilators to 2022" report to their offering.

Asthma and COPD continue to be a health segments that present significant challenges to patients and the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and combination product providers directed toward the development easier-to-use inhalers. Because they relax smooth muscles in the airways, bronchodilators are an indispensable tool for the treatment of upper respiratory diseases. The market entry of combination drug inhalers that deliver a bronchodilator and a corticosteroid from the same inhaler are providing important options for both clinicians and patients.

Highlights

- Analyzes the market for bronchodilator drugs delivered via oral inhalers
- Assesses inhalation device technology for delivering bronchodilators orally, and evaluates product technology issues and evolving market factors
- Provides detailed assessments of orally inhaled bronchodilator product segments, growth prospects and market potential
- Provides market data and forecasts for orally inhaled bronchodilators to 2022
- Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Key Topics Covered:

1. Executive Summary

2. Orally Inhaled Corticosteroid Market Overview

3. The Upper Respiratory Therapeutics Marketspace

• Therapeutic Targets for Orally Inhaled Bronchodilators
• Competing Drug Treatments
• Demand Drivers
• Technology Factors
• Competitive Landscape

4. Asthma Market Risks and Opportunities

5. Global Patient Demographics

• Regional Market Drivers
• Pediatric Asthma -the Growing Therapeutic Need

6. Inhaler Technologies for Delivering Bonchodilators

7. Dry Powder Inhalers

• DPI Formulation Technology
• Characteristics and Parameters
• DPI Excipients and Packaging
• Metered Dose Inhalers
• MDI Device Selection Criteria
• Ease-of-Use Factors
• Nebulizers

8. Inhaled Bronchodilators - Product Analysis, Market Data & Forecasts

9. Albuterol, Proventil HFA (MDI)

• Albuterol, Ventolin HFA (MDI)
• Albuterol, ProAir HFA (MDI)
• Albuterol, Accuneb (Nebulizer)
• Generic Albuterol (Nebulizer)
• Albuterol/Ipratropium (Combuvent) Combination Drug Inhaler (MDI)
• Albuterol/Ipratropium (Duoneb) Combination Drug Solution (Nebulizer)
• Generic Albuterol/Ipratropium Combination Drug Solution (Nebulizer)
• Fluticasone/Vilanterol (Breo Ellipta) Combination Drug Inhaler (DPI) Fluticasone/Salmeterol (Advair HFA) Combination Drug Inhaler (MDI)
• Fluticasone/Salmeterol (Advair Diskus) Combination Drug Inhaler (DPI)
• Formoterol, Foradil (DPI)
• Formoterol, Perforomist (Nebulizer)
• Formoterol/Mometasone (Dulera) Combination Drug Inhaler (MDI)
• Ipratropium, Atrovent HFA (MDI)
• Generic Ipratropium (Nebulizer)
• Levalbuterol, Xopenex (Nebulizer)
• Generic Levalbuterol (Nebulizer)
• Levalbuterol, Xopenex HFA( MDI)
• Salmeterol, Serevent (DPI)
• Tiotropium, Spiriva (DPI)
• Tiotropium, Spiriva Respimat (MDI)
• Umeclidinium, Incruse Ellipta (DPI)
• Umeclidinium/Vilanterol (Anoro) Combination Drug Inhaler (DPI)

10. Market Factors

11. Regulatory Issues

• Patient Compliance
• Prescribing Trends
• Healthcare Economics
• Regional Market Factors
• Connected Devices

12. Market Sector Company Profiles

For more information visit http://www.researchandmarkets.com/research/v3tw68/orally_inhaled

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net